估值2.5亿美元，上海小核酸创新药企冲击IPO，CEO曾在药明康德任职

Core Viewpoint - A Shanghai-based innovative nucleic acid drug company is aiming for an IPO with a valuation of $250 million, and its CEO previously worked at WuXi AppTec [1] Group 1: Company Overview - The company specializes in nucleic acid-based therapeutics, which are gaining traction in the pharmaceutical industry due to their potential in treating various diseases [1] - The CEO's background at WuXi AppTec, a leading global pharmaceutical and biotechnology company, adds credibility and expertise to the company's leadership [1] Group 2: Market Context - The IPO is set against a backdrop of increasing interest in biotechnology and innovative drug development, particularly in the context of personalized medicine [1] - The valuation of $250 million reflects the growing investor confidence in the nucleic acid therapeutics sector, which is expected to expand significantly in the coming years [1]